PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 112 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $288,000 | -37.9% | 34,100 | 0.0% | 0.24% | -17.3% |
| Q1 2022 | $464,000 | -30.8% | 34,100 | 0.0% | 0.28% | -29.2% |
| Q4 2021 | $671,000 | -38.7% | 34,100 | 0.0% | 0.40% | -38.2% |
| Q3 2021 | $1,094,000 | -5.2% | 34,100 | 0.0% | 0.65% | +42.0% |
| Q2 2021 | $1,154,000 | -9.9% | 34,100 | 0.0% | 0.46% | +5.1% |
| Q1 2021 | $1,281,000 | +12.3% | 34,100 | -0.7% | 0.44% | +9.3% |
| Q4 2020 | $1,141,000 | -10.5% | 34,350 | -1.2% | 0.40% | -32.5% |
| Q3 2020 | $1,275,000 | +11.5% | 34,776 | 0.0% | 0.59% | -44.7% |
| Q2 2020 | $1,144,000 | – | 34,776 | – | 1.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $28,143,000 | 7.62% |
| Frazier Life Sciences Management, L.P. | 5,827,415 | $79,311,000 | 6.76% |
| Abingworth LLP | 1,435,106 | $19,503,000 | 5.53% |
| Penn Mutual Asset Management, LLC | 86,940 | $1,183,000 | 1.37% |
| MPM BioImpact LLC | 193,326 | $2,631,000 | 0.71% |
| Avidity Partners Management LP | 1,946,000 | $26,485,000 | 0.55% |
| StepStone Group LP | 422,085 | $5,745,000 | 0.43% |
| Rhenman & Partners Asset Management AB | 235,210 | $3,201,000 | 0.32% |
| Summit Rock Advisors, LP | 34,100 | $464,000 | 0.28% |
| Parkman Healthcare Partners LLC | 65,553 | $892,000 | 0.26% |